Parkinson's drug trial halted early: what happened?

NCT ID NCT06822517

Terminated Disease control Sponsor: Ventus Therapeutics U.S., Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called VENT-02 in 29 people with mild to moderate Parkinson's disease. The drug aims to reduce brain inflammation by blocking a protein called NLRP3. The trial was terminated early, so we don't have clear results on whether it helps symptoms or slows the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VENT-02 (an NLRP3 inhibitor)
What this could lead to: If successful, this could point toward a treatment that slows Parkinson's progression by targeting inflammation in the brain.
What could go wrong: This was a very early, small trial that was terminated, so results are limited. It is unclear if VENT-02 is safe or effective for Parkinson's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Investigative Site

Fountain Valley, California, 92708, United States
Investigative Site

San Jose, California, 95124, United States
Investigative Site

West Hills, California, 91307, United States
Investigative Site

Englewood, Colorado, 80113, United States
Investigative Site

Aventura, Florida, 33180, United States
Investigative Site

Boca Raton, Florida, 33486, United States
Investigative Site

Coral Gables, Florida, 33134, United States
Investigative Site

Coral Springs, Florida, 33067, United States
Investigative Site

Cutler Bay, Florida, 33189, United States
Investigative Site

Daytona Beach, Florida, 32117, United States
Investigative Site

Doral, Florida, 33178, United States
Investigative Site

Jacksonville, Florida, 32256, United States
Investigative Site

Maitland, Florida, 32751, United States
Investigative Site

Miami, Florida, 33135, United States
Investigative Site

Miami, Florida, 33165, United States
Investigative Site

Winter Park, Florida, 32789, United States
Investigative Site

Scarborough, Maine, 04074, United States
Investigative Site

Farmington Hills, Michigan, 48334, United States
Investigative Site

Abington, Pennsylvania, 19001, United States
Investigative Site

Memphis, Tennessee, 38157, United States
Investigative Site

Cypress, Texas, 77429, United States
Investigative Site

Round Rock, Texas, 78681, United States
Investigative Site

Spokane, Washington, 99202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.